Anti-Cytokeratin 20 antibody [EPR1622Y]

• Supplier: Abcam
• Catalog: ab76126
• Prices: $403.00
• Sizes: 100 µl
• Host: Rabbit
• Clonality: Monoclonal
• Isotype: IgG
• Clone: EPR1622Y
• Applications: IHC-F WB IP IHC-P ICC/IF FC
• Species Reactivities: Rat, Goat, Human, Pig, Marmoset
• Antigen: A synthetic peptide from C terminal residues of human Cytokeratin 20
• Description: Rabbit Monoclonal
• Gene: KRT20
• Conjugate: Unconjugated

Product images

Overlay histogram showing LoVo cells stained with ab76126 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Triton X-100 for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab76126, 1/1000 dilution) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H&L) (ab150077) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.

ab76126 at 1/100 dilution staining Cytokeratin 20 in human colon adenocarcinoma by Immunohistochemistry, Paraffin-embedded tissue.

Anti-Cytokeratin 20 antibody [EPR1622Y] (ab76126) at 1/50000 dilution + human small intestine lysate at 10 µgSecondarygoat anti-rabbit-HRP at 1/1000 dilution

developed using the ECL techniquePerformed under reducing conditions.

ab76126 showing positive staining in Colonic adenocarcinoma tissue.

ab76126 showing positive staining in Urinary bladder transitional carcinoma tissue.

ab76126 showing negative staining in Hepatocellular carcinoma tissue.

ab76126 showing negative staining in Breast carcinoma tissue.

Fluorescent immunohistochemical analysis of paraffin-embedded human colonic adenocarcinoma tissue using ab76126. Green-CK20 red-PI

Equilibrium disassociation constant (KD)Learn more about KD Click here to learn more about KD

Product References

Deficiency in metabolic regulators PPARgamma and PTEN cooperates to drive - Deficiency in metabolic regulators PPARgamma and PTEN cooperates to drive

Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW. Am J Pathol. 2013 Feb;182(2):449-59.

Three differentiation states risk-stratify bladder cancer into distinct subtypes. - Three differentiation states risk-stratify bladder cancer into distinct subtypes.

Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, Willingham SB, Pazhanisamy SK, Contreras-Trujillo H, Storm TA, Lotan Y, Beck AH, Chung BI, Alizadeh AA, Godoy G, Lerner SP, van de Rijn M, Shortliffe LD, Weissman IL, Chan KS. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2078-83. doi:

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas - The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas

Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Soeborg H, Knudsen LB. Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E253-64. doi:

Specific activity of cyclin-dependent kinase I is a new potential predictor of - Specific activity of cyclin-dependent kinase I is a new potential predictor of

Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, Nakayama S, Gohda K, Friess H, van de Velde CJ, Ishihara H, Rosenberg R, Kuppen PJ, Janssen KP. Br J Cancer. 2012 Jan 3;106(1):133-40.

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via - mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via

Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, Evers BM. Cancer Res. 2011 May 1;71(9):3246-56.